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Minimal Invasive Ablative Techniques in the Treatment of Breast Cancer: 
a Systematic Review 
Abstract 
Purpose: Breast conserving surgery is effective for breast cancer treatment but is associated 
with morbidity in particular high re-excision rates.  We performed a systematic review to 
assess the current evidence for clinical outcomes with minimally invasive ablative techniques 
in the non-surgical treatment of breast cancer.  
Methods: A systematic search of the literature was performed using PubMed and Medline 
library databases to identify all studies published between 1994 and May 2016. Studies were 
considered eligible for inclusion if they evaluated the role of ablative techniques in the 
treatment of breast cancer and included ten patients or more. Studies that failed to fulfil the 
inclusion criteria were excluded. 
Results: We identified 63 studies including 1608 patients whose breast tumours were treated 
with radiofrequency (RFA), high intensity focused ultrasound (HIFU), cryo-, laser or 
microwave ablation. Fifty studies reported on the number of patients with complete ablation 
as found on histopathology and the highest rate of complete ablation was achieved with RFA 
(87.1%, 491/564) and microwave ablation (83.2%, 89/107). Short-term complications were 
most often reported with microwave ablation (14.6%, 21/144). Recurrence was reported in 24 
patients (4.2%, 24/570) and most often with laser ablation (10.7%, 11/103). The shortest 
treatment times were observed with RFA (15.6±5.6 minutes) and the longest with HIFU 
(101.5±46.6 minutes).  
Conclusion: Minimally invasive ablative techniques are able to successfully induce 
coagulative necrosis in breast cancer with a low side effect profile. Adequately powered and 
prospectively conducted cohort trials are required to confirm complete pathological ablation 
in all patients. 
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Keywords: Ablative techniques, radiofrequency ablation (RFA), laser-ablation, cryo ablation, 
high intensity focused ultrasound (HIFU), microwave ablation, breast cancer. 
 
Introduction 
Breast cancer is now diagnosed at an earlier stage due to the wider use of breast cancer 
screening and use of more advanced imaging modalities including magnetic resonance 
imaging (MRI). [1, 2] In view of this, more patients are suitable for breast conserving surgery. 
[3, 4] Although breast conserving surgery is effective, it is associated with high re-excision 
rates of 20% in the United Kingdom due to its dependence on clear margins and the surgeon’s 
inability to visualize the tumour extent intra-operatively. [5] Furthermore it can be associated 
with poor cosmetic outcome. [6, 7] There is thus a clinical need to develop non-operative 
techniques in order to treat patients with both tissue and volume preservation. Potential 
advantages of a non-operative approach to breast cancer treatment are the ability to image the 
tumour intra-operatively, reducing the surgical excision rate, reducing treatment cost and 
thereby potentially improving patients’ quality of life. Additional associated potential 
advantages include reducing the rate of general anaesthesia, reducing the complication rate 
and severity of these, reducing recovery time and reducing scarring. [5, 8] In addition, 
adjuvant therapy may be administered faster after ablative treatment, in the absence of a 
wound requiring healing.  
Numerous articles have evaluated novel ablative techniques for the non-operative 
treatment of breast cancer and it is clinically important to evaluate the evidence in order to 
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identify the most promising techniques for further clinical evaluation. [9] We performed a 
systematic review to assess the current evidence on clinical outcomes of minimally invasive 
ablative techniques for the non-operative treatment of breast cancer. 
 
Methods 
Study Selection 
A systematic review of the literature was performed using PubMed and Medline library 
databases to identify all studies published between 1994 and May 2016 that evaluated the role 
of ablative techniques for the treatment of breast cancer. The MESH terms used were ablative 
techniques, ablative interventions, ablative therapy, thermal ablation, high intensity focused 
ultrasound (HIFU), radiofrequency ablation (RFA), laser ablation, cryo-ablation, stereotactic 
radiotherapy and microwave ablation in combination with breast and cancer. Except for 
reports in the English language and human subjects, there were no further restrictions. The 
related articles function was used to broaden the search and identify alternative ablative 
techniques. References of the articles acquired were also searched by hand. The last search 
was conducted on June 7th, 2016. 
Inclusion Criteria 
Studies were considered eligible if they addressed the following: (1) studies performed on 
human subjects with breast cancer, (2) studies evaluating the role of a minimally invasive 
ablative technique, (3) studies with ten or more patients included. 
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Exclusion Criteria 
Studies that failed to fulfil the inclusion criteria were excluded. Conference articles, letters, 
editorials and case reports were excluded from the study. Studies using laser as a surgical 
scalpel (without ablation), or studies using an ablative technique after surgical excision of the 
tumour were excluded. In the case of studies with overlapping populations, the most recent 
study with histopathological outcomes was included. Abstracts of studies that are as yet 
unpublished (full text not available) were excluded. 
Data Extraction 
Each study was initially evaluated for either inclusion or exclusion. One reviewer, (M.P) 
extracted data for all selected studies and a second reviewer (M.A) verified the accuracy of 
the extracted data. In case of a disagreement the senior author (M.D) made the final decision. 
Risk of Bias in Individual Studies 
The “Risk of bias” tool presented in the Cochrane Handbook [10] was used to determine the 
suitability of randomized control trials (RCT). The study quality of cohort studies was 
assessed according to the recommendations of the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement. [11] Seven items of the 
STROBE statement were considered relevant for quality evaluation. These included clearly 
reported objectives and inclusion criteria, usage of a standardised technique, standardised 
histopathology and standardised imaging, patient follow-up and reporting of any withdrawals 
from the study. Studies with a score of less than four were excluded. Two reviewers (M.P and 
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M.A) performed the assessment independently. In case of a disagreement, a consensual 
decision was reached. 
Statistical Analysis 
All extracted data were tabulated and presented as means, standard deviations (SD) and 
percentages. Numerators and denominators were provided to address outcomes of included 
studies.  
A meta-analysis was undertaken using a random effect logistic model given the wide 
variation in complete ablation percentages between studies. Parameter estimation was 
performed by a maximum-likelihood fit. To check the methodology, a parametric bootstrap 
technique was used [12] to correct bias using maximum-likelihood estimates. From the 
bootstrapped solutions, standard errors (s.e.), significance tests and confidence intervals (CI) 
were calculated. In addition, an analysis of covariance was performed to determine any 
correlation between the treatment time and treated tumour size.  
JU
ST
 AC
CE
PT
ED
  
Results 
Selected Studies 
A total of 2044 articles published between 1994 and May 2016 were identified from the 
literature search (figure 1). Three additional articles were identified by searching the 
references of selected articles. After reviewing the title and abstracts, 1930 articles were not 
deemed relevant and were excluded leaving 114 articles for full text examination. Several 
studies using techniques such as stereotactic radiotherapy and Gadolinium enhanced RODEO 
laser ablation were excluded as they did not meet the inclusion criteria (less than ten patients 
included). A total of 63 articles matched the selection criteria. The 63 articles included 16 
feasibility studies [13-28], 12 phase I studies [29-40], nine phase II studies [41-49], three 
comparative studies [50-52], one retrospective study [53], and four randomised controlled 
trials [54-56]. In 18 studies the type of study was not reported [8, 57-73]. One article [54] 
contained the results of four studies of which two were previously published. [39, 41] All four 
studies (one phase I [39], one phase II [41] and two randomised controlled trials [54]) were 
included in this systematic review. 
Study Characteristics 
In total, 63 studies with 1608 patients and 1627 breast cancers, were included in the 
systematic review. The characteristics of the studies are summarized per technique in table’s 
1a-e. Radiofrequency ablation (RFA) was used in 27 studies (657 patients) [13-17, 26, 27, 29-
32, 42-48, 51, 64-71], in which a needle electrode is percutaneously inserted under ultrasound 
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(US) guidance to deliver an alternating current that generates ionic agitation, localised tissue 
heating and cell death. [32, 46, 74] Twelve studies used high intensity focused ultrasound 
(HIFU) (227 patients) [8, 23, 24, 38, 52, 55-60, 72], a completely non-invasive ablative 
technique in which a focused US beam propagates through tissue as a high frequency pressure 
wave causing the temperature to rise, leading to protein denaturation and coagulative necrosis. 
[55, 75-77] Ten studies used cryo-ablation (269 patients) [19-22, 35-37, 49, 61, 73], in which 
a probe is inserted into the tumour under US guidance. The ablation process involves two 
phases: freezing and thawing with four mechanisms destroying the tumour cells: direct 
damage by intracellular ice formation and osmotic dehydration and indirect damage due to 
ischemia and immunologic response. [36, 78] Seven studies used laser-ablation (231 patients) 
[18, 28, 33, 34, 50, 62, 63], in which lesions are ablated due to direct heating with low-power 
laser light energy delivered percutaneously via thin optical fibres. Upon absorption in the 
tissue, heat is produced, inducing lethal thermal injury. Six studies used microwave ablation 
(144 patients) [25, 39-41, 54], which uses localised heating caused by water molecules which 
move within tissues, and externally applied focused microwaves to cause tissue necrosis. This 
technique can heat and damage high-water-content tumour cells, whilst tissues with lower-
water-content such as adipose and breast glandular tissues remain unharmed. [41, 79] One 
study [53] compared cryo-ablation with RFA (80 patients).  
All but two studies treated patients with malignant breast tumours, one study treated 
newly diagnosed breast cancer and breast recurrences [21] and one treated breast recurrences 
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only. [43]. For image guidance of the ablative techniques, US was used by all five ablative 
techniques in 44 studies [13-20, 22, 24-27, 29-36, 39, 40, 42-51, 53, 55, 56, 64-71], magnetic 
resonance imaging (MRI) in 11 studies using HIFU and cryo-ablation. [8, 23, 37, 38, 52, 57-
61, 72]Two cryo-ablation studies [21, 73] and one laser ablation study [28] used computer 
tomography (CT) in combination with US and two laser ablation studies [62, 63] used 
stereotactic guidance. In three microwave studies the imaging modality is not known. [41, 54] 
The ablative treatments were performed by the surgeon in six studies [25, 26, 35, 48, 56, 62], 
radiologist in four studies [15, 31, 45, 64], a combination of both in one study [40] and 52 
studies did not report on who performed the treatment. 
There are some important differences between the ablative techniques. The benefit of 
HIFU is that insertion of a probe is not required as this technique is completely non-invasive 
and scar less. Cryo-ablation and microwave ablation require the insertion of a single probe 
and RFA and laser ablation require the insertion of multiple probes. Furthermore, cryo-
ablation is the only to use freezing rather than heat to cause tumour necrosis. 
 
Quality Assessment 
Seven items of the STROBE statement [11] were used for quality assessment of the included 
cohort studies (table 2a). All studies included specified study objectives and all but eight [28, 
33, 37, 39, 50, 51, 60, 61] had clear inclusion criteria. A standardised technique was used in 
all but five studies [23, 26, 27, 36, 57], all but seven studies reported standardised 
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histopathology [19, 23, 33, 38, 52, 58, 60] and standard imaging was performed in 30 studies 
[8, 16, 17, 21-24, 26-28, 31, 32, 34, 37, 38, 40, 46, 47, 50, 52, 53, 57-60, 66-68, 72, 73]. 
Patient follow-up, in the case of no surgical excision or after surgical excision of breast cancer 
was undertaken in 17 studies [21, 22, 24, 28, 30, 31, 33, 34, 42, 44, 52, 60, 66-68, 70, 73], 
however, 14 studies [17, 18, 26, 27, 40, 45-47, 49, 50, 53, 62, 63, 72] reported follow-up only 
until delayed surgical excision. In four studies [16, 32, 65, 69], a group of patients underwent 
immediate surgical excision of the tumour and the remaining patients were followed up until 
surgical excision. In five studies [21, 24, 49, 59, 63], patients withdrew from the study during 
or after treatment and in another six studies [15, 26, 44, 48, 49, 72] patients withdrew before 
the start of the treatment. The overall STROBE score ranged from four to seven (mean 
5.4±0.9).  
For the four included RCTs [54-56], the Cochrane checklist [10] was used (table 2b). 
All studies had unspecified sequence generations (selection bias) and allocated concealment 
(selection bias). All studies did not perform a power calculation or any blinding of the 
participants or personnel (performance bias) or outcome assessment (detection bias, patient-
reported outcomes and mortality). The second study by Dooley et al. [54] included 
incomplete data addresses (attrition bias; short- and longer-term outcomes missing) and all 
studies were free of selective reporting (selection bias) or other biases.  
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Outcomes 
Histopathology 
Post-treatment surgical excision of tumours was performed in 52 studies (1339 patients) in 
which immediate surgical excision was performed in 16 studies (387 patients, most often with 
RFA) [13-15, 18, 25, 26, 29, 35, 42-45, 48, 51, 64, 71], delayed surgical excision in 33 studies 
(853 patients) [8, 17, 19, 20, 22, 27, 28, 33, 34, 36-41, 46, 47, 49, 50, 52-59, 61-63, 67, 70, 
72] and a combination of immediate and delayed surgical excision in three studies (99 
patients) [16, 65, 69]. A combination of follow-up and immediate or delayed surgical excision 
was performed in two studies (49 patients).[32, 33] Follow-up with imaging alone or imaging 
and core biopsies was performed in nine studies (220 patients) [21, 23, 24, 30, 31, 60, 66, 68, 
73]. Reasons for performing a treat and resect study or a follow-up study were often not 
reported. Follow-up was performed in studies with patients unsuitable or not willing to have 
surgical excision. Immediate surgical excision was performed to determine the true zone of 
necrosis and delayed surgical excision was performed to determine the degenerative changes 
over time. 
Delayed surgical excision was performed within a week of treatment in four studies 
[19, 33, 50, 72] (most often following laser ablation), within two weeks of treatment in ten 
studies [8, 20, 27, 34, 36, 38, 55, 56, 58, 59] (most often following HIFU), within three weeks 
of treatment in eight studies [17, 28, 39, 41, 46, 47, 54, 62] (most often following RFA), 
within four weeks of treatment in four studies [37, 40, 49, 67] and longer than four weeks of 
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treatment in six studies [22, 52, 53, 61, 63, 70]. In two studies the timing of surgical excision 
in relation to treatment was not reported [54, 57]. In the three combination studies [16, 65, 69] 
(all RFA studies), delayed surgical excision was performed after a longer period ranging from 
1-40 months. 
Complete ablation on histopathology was reported in 50 studies. Considering RFA, in 
87.1±12.8% (491/564) of all patients who underwent surgical excision, complete ablation of 
the tumour was achieved [13-17, 26, 27, 29, 32, 42-48, 51, 53, 64, 65, 67, 69-71] (table 1a). 
For laser ablation, 52.2±29.2% (48/92) of all patients had complete ablation post-treatment 
[18, 34, 63] (table 1b) and for cryo-ablation, complete ablation was achieved in 74.1±28.9% 
(186/251) of all patients [19, 20, 22, 35-37, 49, 53, 61] (table 1c). With HIFU, complete 
ablation was achieved in 47.6±29.9% (60/126) of all patients [8, 38, 52, 55, 57-59] (table 1d) 
and in microwave ablation 83.2±11.6% (89/107) of patients obtained complete ablation [25, 
41, 54] (table 1e).  
Using a random effect logistic model given the wide-variation in complete ablation 
rates between studies, the probabilities of success to achieve complete pathological response 
for the five ablative techniques with 95% CI were calculated. The highest estimate was for 
RFA (0.87 (0.82, 0.91)), followed by microwave ablation (0.81 (0.70, 0.93)), cryo-ablation 
(0.75 (0.70, 0.85)), laser ablation (0.71 (0.67, 0.82)) and HIFU (0.71 (0.67, 0.79)) (figure 2). 
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When looking at complete ablation rates of RFA studies that followed patients up with 
core needle biopsy (CNB) and imaging but without surgical excision, complete ablation was 
achieved in 98.0±4.0% (100/102) [30, 32, 66, 68], in follow-up studies using cryo-ablation 
100% (6/6) of patients had complete ablation [21] and in follow-up studies using HIFU 
89.1±14.8% (41/46) of patients had complete ablation. [23, 24] 
Follow-up: 
Follow-up was performed in all [21, 23, 24, 30, 31, 60, 66, 68, 73] or in a cohort of patients 
[32, 33] in eleven studies. Follow-up was performed with MRI (n=3), US (n=1) and cytology 
(n=1) in RFA studies [30-32, 66, 68] with a mean follow-up period of 28.1±15.6 months; with 
CT (n=1) and MRI (n=2) in cryo-ablation studies [21, 73] with a follow-up of 18.7±5.8 
months; with MRI (n=3), US (n=2), SPECT (n=1) and core biopsies (n=1) in HIFU studies 
[23, 24, 60] with a mean follow-up period of 29.7±22.0 months and with US (n=1), CT (n=1) 
and core biopsies (n=1) in laser ablation studies with a mean follow-up of 20.5±0 months.[33] 
Treat and resect studies also undertook patient follow-up. RFA studies used MRI 
(n=6), US (n=4), mammography (n=2) or CT (n=1) for follow-up up to one month after 
surgical excision, laser ablation studies used MRI (n=2), US (n=1), CT (n=1) and 
mammography (n=1) for follow-up up to two weeks after surgical excision and every three 
months thereafter, cryo-ablation studies used MRI (n=3) or US (n=1) for follow-up up to one 
month after surgical excision, HIFU studies used MRI (n=5) for follow-up up to three weeks 
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after surgical excision, and microwave ablation studies used MRI (n=1) or US (n=1) up to 
three weeks prior to surgical excision. 
Margins: 
Fifteen studies reported on treating an additional margin of normal breast tissue around the 
tumour. Six RFA studies treated a margin of 5mm (n=3) [29, 42, 44] or more than 5mm 
(n=3). [13, 27, 45] One laser ablation study treated an additional 5mm of normal breast tissue. 
[62] Two cryo-ablation studies treated an additional margin of 5-10 mm of normal tissue. [35, 
37] Six HIFU studies treated a margin of 5 mm (n=3) [8, 38, 52] or 15-20 mm (n=3).[24, 55, 
56]  
Axillary lymph nodes: 
The type of axillary treatment was reported in 40 studies. Axillary treatment was performed 
prior to ablative treatment (n=17), after ablative treatment (n=2), along with surgical excision 
(n=14), or the timing was not specified (n=7). Sentinel lymph node biopsy (SLNB) in 
immediate surgical excision studies was often performed just prior to the ablative treatment, 
which was then followed by surgical excision of the tumour. For delayed surgical excision, 
SLNB was often performed along with surgical excision of the tumour or prior to the ablative 
treatment in order to perform an axillary clearance (if necessary) simultaneously with the 
surgical excision. For follow-up studies, SLNB was performed prior to ablative treatment. In 
the case of clinically or radiologically positive nodes or positive nodes after SLNB, an 
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axillary node clearance was performed instead or after involved nodes were removed during 
SLNB.  
A total of 187 positive nodes were found in the ablative studies, 103 with RFA, 20 
with cryo-ablation, 17 with laser and microwave ablation and 15 with HIFU and the combined 
study (RFA and cryo ablation). 
Local Recurrence: 
Local recurrence was reported in 24 patients from nine studies (24/570, 4.2%). Most local 
recurrences were reported with laser ablation (10.7%, 11/103) [33, 34] at a mean follow-up 
time of 20.5±0 months, and RFA (3.1%, 9/291) [31, 42, 64, 69] at a mean follow-up time of 
30.8±16.9 months. No local recurrences were reported with microwave ablation, (0/144) one 
case of local recurrence was reported with cryo-ablation (1.4%, 1/74) [73] at a mean follow-
up time of 16.9±2.0 months and three cases with HIFU (2.9%, 3/102) [24, 60] at a mean 
follow-up time of 21.4±19.3 months. 
Recurrences were documented in two studies (n=3) who performed immediate surgical 
excision [42, 64], one study (n=2) with delayed surgical excision [34], one study (n=3) with 
combined immediate and delayed surgical excision [69], one study with combined delayed 
surgical excision (n=8) and follow-up (n=1) [33] and three studies (n=7) who performed 
follow-up only [24, 31, 60, 73].  
JU
ST
 AC
CE
PT
ED
  
Post-Treatment Short-Term Complications 
Complications were reported in 9.0% of all patients (123/1258). The most common 
complications were skin burns (3.5%, 44/1258), pectoralis major muscle damage (1.1%, 
14/1258), seroma (0.6%, 8/1258), skin necrosis (0.6%, 7/1258) and ecchymosis (0.6%, 
7/1258). Other reported complications were blistering (0.5%, 6/1258), hematoma (0.4%, 
5/1258), coagulative changes to the skin (0.4%, 5/1258), nipple retraction (0.3%, 4/1258), 
pneumothorax (0.2%, 3/1258), flap necrosis (0.2%, 3/1258), fever (0.2%, 3/1258), infection 
(0.2%, 2/1258), skin puckering (0.2%, 2/1258), skin retraction (0.2%, 2/1258) and single 
cases (0.1%, 1/1258) of overreaction of the ablated zone, fistula, white lumps on treated area, 
haemorrhage, arterial bleeding,  tumour rupture and abscess. All complications were device 
related rather than cancer specific complications, and thus far, only one of the nine studies 
[21, 23, 24, 30, 32, 60, 66, 68, 73] without surgical excision of the ablated tumour post-
treatment, documented longer-term complications, one patient (0.1%, 1/1258) with skin 
retraction which turned into skin ulceration at 12 months follow-up. 
With RFA, 10.5% of patients developed post-treatment complications (58/555) of 
which 23 were skin burns [14-16, 26, 27, 29-32, 42, 47, 48, 66, 67], 12 muscle burns [14, 15, 
48], five cases of blistering [51], four of coagulative changes to the skin [51], three were cases 
of ecchymosis [27, 46], three cases of nipple retraction, [31] two case of pneumothorax [15, 
64], two incidences of skin puckering [44], two infections [42, 44] and single cases of 
overreaction [30] and fistula [47] (table 1a). With cryo-ablation 10.9% of patients (20/183) 
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developed a complication, these were skin necrosis (n=5) [61], haematoma (n=5) [22, 73], 
ecchymosis (n=4) [22], skin retraction (n=2) [73], seroma (n=2) [19, 20], arterial bleeding 
(n=1) [20] and skin ulceration (n=1). [73] Several patients also developed skin burns and 
mastitis (number unreported) [37] (table 1c). With laser ablation 6.3% of patients (12/191) 
developed complications, which included skin burns (n=7) [18, 33, 63], necrosis (n=2) [34], 
haemorrhage (n=1) [28], pneumothorax (n=1) [18] and rupture of the tumour (n=1) [33] (table 
1b). With HIFU complications occurred in 6.5% of patients (12/185) which included skin 
burns (n=8) [8, 23, 38, 55, 57, 60], fever (n=3) [56] and white lumps at the treatment site 
(n=1) [72] (table 1d). Microwave ablation resulted in the most complications (14.6%, 21/144), 
which included skin burns (n=6) [41, 54], seroma (n=6) [54], flap necrosis (n=3) [39], muscle 
burns (n=2) [25], blistering(n=1) [39], coagulative changes to the skin (n=1), [25] abscess 
(n=1) [25, 54] and nipple retraction (n=1) [54] (table 1e). 
Treated Tumour Sizes 
Considering the size of treated tumours, microwave ablation was used to treat the largest 
tumours, with a mean tumour diameter of 2.7±1.1 cm (six studies) [25, 39-41, 54]. HIFU was 
used to treat tumours of 2.1±0.9 cm (seven studies) [8, 23, 24, 38, 52, 55, 72], and cryo-
ablation was used to treat tumours with a mean size of 1.6±0.7 cm (eight studies) [19, 21, 22, 
35-37, 49, 61]. The smallest tumours were treated with laser-ablation (1.2±0.2 cm, three 
studies) [34, 62, 63] and RFA (1.5±0.4 cm, 17 studies), [13, 15, 29, 30, 42, 44-48, 51, 65-69, 
71] Only mean sizes were included in this analysis (table’s 1a-e). 
JU
ST
 AC
CE
PT
ED
  
Total Treatment Duration 
Considering treatment duration, RFA had the shortest mean treatment time of 15.6±5.6 
minutes (20 studies) [13-15, 29-31, 42-46, 48, 51, 53, 64-68, 70]. Laser ablation had a mean 
treatment time of 25.7±6.1 minutes (two studies) [18, 34] and microwave ablation had a mean 
treatment time of 19.0±18.2 minutes (four studies) [25, 39, 40, 54]. Cryo-ablation had a much 
longer mean treatment time of 50.3±58.4 minutes (seven studies) [19, 21, 35-37, 61, 73] and 
HIFU the longest mean treatment time of 101.5±46.6 minutes (four studies). [8, 52, 57, 72] 
Only mean treatment times were included in this analysis (tables 1a-e).  
An analysis of covariance’s initially showed a significant increase in treatment time 
with tumour size. Correcting for tumour size, showed that microwave ablation was the 
quickest technique, followed by RFA, laser ablation, cryo-ablation and HIFU. A purpose 
written Fortran program and RFA as a baseline showed the following estimates (95% CI): 
MW 0.32 (0.15, 0.68), RFA 1.0 (1.0, 1.0), laser ablation 1.27 (0.76, 2.11), cryo-ablation 2.58 
(1.69, 3.96) and HIFU 5.03 (3.15, 8.02). Unfortunately, on replacing tumour sizes by rank 
size, no significant relationship between the treatment time and tumour size was found. The 
apparent strong dependence of treatment time on tumour size was shown to be spurious, and 
driven by outlying studies with large tumour sizes and long treatment times. 
Cosmetic Outcome: 
Cosmetic outcome was reported in nine studies using RFA, HIFU and cryo-ablation. Seven 
studies [30, 32, 42, 53, 66, 67, 70] using RFA reported an excellent cosmesis in 85.3% of 
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patients (168/197), good cosmesis in 9.6% (19/197), acceptable cosmesis in 0.5% (1/197), fair 
cosmesis in 2.5% (5/197), poor cosmesis in 1.5% (3/197) and cosmesis was unknown in 0.5% 
(1/197). Cosmesis was collected using a 1-4 point scaling system (n=4), a 1-10 point scaling 
system (n=1) or it was not reported (n=2). The cosmesis was evaluated by the consultant 
(n=3), the patient (n=2) or this was not reported (n=2) and it was evaluated four weeks after 
treatment (n=2), one year after treatment (n=1), at one, three and six months after treatment 
(n=1) or not reported (n=3). No surgical excision was performed in three studies [30, 32, 66] 
and delayed surgical excision was performed in three studies [53, 67, 70] and the cosmesis in 
these six studies was evaluated prior to surgical excision. In one study, [42] immediate 
surgical excision was performed and cosmesis was evaluated after surgical excision (excellent 
(12), good (3) cosmesis). 
With HIFU [24, 38], 59.3% of patients (16/27) graded their cosmetic outcome as good and 
7.4% (2/27) as acceptable and cosmesis was unknown in nine patients (9/27, 33.3%). One 
follow-up study [24] evaluated the cosmesis using a 1-5 point scale at the last follow-up and 
cosmetic evaluation was undertaken by the consultant. The other study [38] performed 
delayed surgical excision and did not report on the methods used to evaluate cosmesis. With 
cryo-ablation [53], excellent cosmesis was reported in 92.5% (37/40) of patients, good 
cosmesis in 5.0% (2/40) and acceptable in 2.5% (1/40). This study performed delayed surgical 
excision and the cosmesis was evaluated by the consultant after four weeks, using a 1-4 point 
scaling system. 
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Discussion 
The trials conducted to date demonstrate feasibility and potential benefits for minimally 
invasive ablative treatment of breast cancer. However, ablative techniques are generally being 
evaluated in small, often uncontrolled studies that are unlikely to change clinical practice or 
provide the basis for phase III trials. The trials in this systematic review also included four 
RCTs but none of these carried out adequate sample size calculations. Therefore a deficiency 
of this systematic review is the limited quality of published studies in this field. 
The most important outcome measures are completeness of ablation, complication rate 
and tumour recurrence. In terms of complete ablation, the best outcomes are reported with 
RFA (87.1%, 491/564), microwave ablation (83.2%, 89/107) and cryo-ablation (74.1%, 
186/251). Limitations exist in the comprehensive recording of reported histopathological 
outcomes. The most reliable way to determine cell death (especially immediately post-
surgical excision) is with nicotinamide adenine dinucleotide (NADH) staining. However this 
type of staining was not always used. [16] With respect to radio-pathological correlation, 
more concordance with imaging was observed with NADH assessment of necrosis compared 
to haematoxylin and eosin (H&E). 
The histopathology results in almost all studies described the number of patients with 
complete ablation. In patients with partial ablation, the percentage of viable tumour seen 
within the ablated zone, was only reported in three studies [57, 58, 61]. Several studies used 
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biopsies of the ablated zone to evaluate completion of tumour ablation. With respect to 
percentages of complete ablation and mean tumour size, no direct comparison can be made 
because of study heterogeneity. Rate of complete ablation cannot be controlled for lesion size, 
since lesion size was not consistently reported in each study.  
The most common complications were skin burns which occurred in 3.5% of patients 
(44/1258, most in RFA) and damage to the pectoralis major muscle which was reported in 
1.1% of patients (14/1258, most in RFA). With respect to treatment related complications 
laser ablation (6.3%, 12/191) and HIFU (6.5%, 12/185) have the fewest complications and 
most complications were reported with microwave-ablation (14.6%, 21/144). However, 
complications may be under-reported since some such as pain, oedema and erythema are not 
consistently reported in all studies. Some studies only report severe complications and others 
report all complications. Furthermore, not all studies evaluated the level of pain during and 
after treatment. Skin burns were the most serious complication described, and likely causation 
was not described in most studies, however in some studies the burn may have been caused by 
a short lump-skin distance or therapy was performed immediately after biopsies were taken. 
Only one longer-term complication was reported in the nine studies, without surgical excision 
of the ablated tumour post-treatment. All other studies included only short-term complications 
up until surgical excision. Large prospective trials with long-term follow-up of at least five 
years are required to determine the long-term complications.  
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Local recurrence occurred following 11 laser, nine RFA, three HIFU and one cryo-
ablation treatment, however only 22 studies looked at the recurrence rates, including all nine 
follow-up studies. With respect to cosmesis, patients treated with cryo-ablation and RFA 
seem to have a better cosmesis post-treatment compared to pre-treatment than patients treated 
with HIFU. However, HIFU is a completely non-invasive technique which requires no 
incision whilst all the other techniques do require a small incision. Therefore HIFU is 
expected to achieve a better cosmesis. In addition, the only complications reported with HIFU 
were skin burns, whilst all other ablative techniques reported complications related to the 
insertion of the needle or probe. 
Analysis of mean treatment duration, demonstrated that RFA (15.6±5.6 minutes), laser 
(25.7±6.1 minutes) and microwave ablation (19.0±18.2 minutes) have the shortest treatment 
time. Analysis of covariance was difficult due to inconsistent methods of reporting tumour 
sizes and treatment times. After replacing tumour sizes by their ranks, no significant 
relationship was found. Clearly, the choice of ablative technique in individual studies was 
based on access or availability of the technique rather than a conscious selection based on 
which ablative technique has the shortest treatment times or showed highest complete ablation 
rates. 
The limitation of this study is that only four RCTs [54-56] and one retrospective 
analysis comparing two techniques [53] were included and therefore a comparative meta-
analysis could not be performed. The RCTs compared HIFU and microwave ablation with 
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breast conserving surgery [54-56] or microwave ablation with neo-adjuvant chemotherapy 
with chemotherapy alone [54]. When considering histopathology, treatment time and 
complications, RFA demonstrated the most promise of any minimally invasive technique for 
the non-surgical treatment of breast cancer, but RFA is not included in the RCTs. More RCTs 
comparing ablative techniques with surgical excision or with each other (including RFA) are 
needed with sample size calculations to accurately evaluate differences between the 
techniques. However, initially adequately powered cohort trials should be conducted to 
confirm complete pathological ablation in all patients is feasible. This can be obtained by first 
developing a predictive tool for assessing complete ablation within treat and resect studies, by 
imaging the tumour post-treatment prior to surgical excision and verifying the extent of 
ablation on imaging with histopathological correlation. And secondly by using this predictive 
tool in follow-up studies to determine the amount of complete ablation. Once efficacy to 
achieve complete pathological ablation is confirmed, RCTs comparing the most promising 
ablative technique to surgical excision can be conducted to determine long-term treatment 
related and cancer specific complications.  
Another limitation is that the cohort studies included, have considerable heterogeneity. 
It is therefore not possible to perform a quantitative comparison between the studies. 
Compared to breast surgery, these techniques have the advantage of intra-operative imaging 
to improve accuracy during the treatment. Other potential benefits are the low and less severe 
complication rates, minimal invasiveness of the techniques resulting in a short hospital stay 
JU
ST
 AC
CE
PT
ED
  
and recovery time which might lead to a reduction in treatment cost compared to breast 
surgery. [8, 9, 80] Also adjuvant therapy may be administered faster after ablative treatment, 
in the absence of a wound requiring healing. All the trials treated patients with invasive breast 
cancer or breast recurrences, for the treatment of ductal carcinoma in-situ the challenge is the 
lack of reliable imaging tools for real-time treatment planning and assessment of response to 
treatment. However, the disadvantage of these techniques is axillary staging as surgery is still 
required in patients with early breast cancer to perform SLNB. 
 
Conclusion 
Minimally invasive ablative techniques are able to successfully induce coagulative necrosis 
with a low side-effect profile but complete ablation is not achieved consistently. The best 
response in terms of complete ablation was reported following RFA and the fewest 
complications were reported following HIFU treatment. Adequately powered and 
prospectively conducted cohort trials are required to confirm complete pathological ablation is 
achievable in all patients and to develop a predictive tool for assessing complete ablation. 
Once this is confirmed, RCTs comparing the most promising ablative technique to surgical 
excision can be conducted to determine long-term treatment related and cancer specific 
complications.  
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Figures and Tables 
Figure 1. PRISMA 2009 Flow Diagram 
Figure 2. Probabilities of success to achieve complete pathological response with 95% 
confidence intervals calculated using a random logistic effect model. 
Table 1. Study characteristics and outcomes for (a) radio-frequency, (b) laser, (c) cryo, (d) 
high intensity focused ultrasound and (e) microwave ablation. 
Table 2. Quality assessment (Yes/No) for (a) cohort studies and (b) randomized controlled 
trials.  
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Table 1a: Study characteristics and outcomes for radiofrequency ablation (RFA) 
Study N Size 
lesion 
(cm)* 
Age 
(years)
* 
Electrode
+
 CA  Resection* Complicatio
ns  
Treatme
nt time 
(min)* 
Izzo (2001) 26 1.8  
(0.7-
3.0) 
57 (37-
78) ¹ 
LeVeen 96% 
(NADH) 
Immediatel
y 
Skin burn (1) 15.4 (6.4 
- 24.9) 
Burak 
(2003) 
10 1.2  
(0.8-
1.6) 
53.7  
(37-67) 
RadioTherapeut
ics 
90% 
(H&E) 
16.1 (8-24) 
D 
Ecchymosis 13.8 (7-
21) 
Hayashi 
(2003) 
22 0.9  
(0.5-
2.6) ¹ 
73 (60-
80) ¹ 
StarBurst 86% 
(NADH, 
H&E) 
1-2 wk Skin burn 
(1), 
Ecchymosis 
(2) 
15 (15-
20.5) ¹ 
Singletary 
(2003) 
29 <2.0 - RITA Model  500 
/ Starburst 
86% 
(NADH, 
H&E) 
Immediatel
y 
Skin burn (1) 30-45 
Fornage 
(2004) 
20 
(21) 
1.2±0.
3  
(0.6-
2.0) 
56±11  
(38-80) 
StarBurst 100% 
(NADH) 
Immediatel
y 
 21.2 
(18.9-29)  
Noguchi 
(2006) 
10 1.1  
(0.5-
2.0) 
54 (33-
70) 
StarBurst 100% 
(NADH) 
Immediatel
y 
- 18 (17-
19.5) 
Earashi 
(2007) 
17+
7 
1.1  
(0.5-
2.4) 
and 
1.1  
(0.7-
2.0) 
55 (33-
78) and 
44  
(29-55) 
StarBurst 100% 
(NADH) 
Immediatel
y (n=17), 
delayed 
(n=7) by 
mammoto
me  
91 (30-202) 
D¹ 
- 18 (17-
21.5) 
Khatri 
(2007) 
15 1.28  
(0.8-
1.5) 
63 (39-
83) 
Cool-Tip 93% 
(NADH) 
Immediatel
y 
Skin 
puckering 
(2), 
infection (1) 
21 (7-36) 
Oura 52 1.3  55 (37- Cool-Tip 100% Follow-up  Skin burn (1) 12 (5-25) 
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Study N Size 
lesion 
(cm)* 
Age 
(years)
* 
Electrode
+
 CA  Resection* Complicatio
ns  
Treatme
nt time 
(min)* 
(2007) (0.5-
2.0) 
83) (CNB) 15 (6-30) M 
Garbay 
(2008) 
10 1.4  
(1.0-
2.2) ¹ 
50 (44-
70) ¹ 
LeVeen 75% 
(NADH, 
n=8), 
70% 
(H&E, 
n=10) 
Immediatel
y 
- 10.7 (5.3 
- 16.0) 
Medina-
Franco 
(2008) 
25 2.1  
(0.9-
3.8) 
55.3  
(42-89) 
Elektrotom 76% 
(NADH) 
Immediatel
y 
Skin burn 
(3), skin 
infection (1), 
recurrence 
(2) 
11 (9-15) 
Imoto 
(2009) 
30 1.7  
(0.9-
2.4) ¹ 
38-76 LeVeen 92% 
(NADH), 
87% 
(H&E) 
Immediatel
y 
Skin burn (2, 
incl skin 
necrosis(1)), 
pectoralis 
major burn 
(7) 
18 (4-42) 
Manenti 
(2009) 
34 1.9±0.
6 (1.7-
2.0) 
53±5  
(49-62) 
Cool-Tip 97% 
(NADH) 
4 wk Skin burn (1) 27±3.7  
(25-35) 
Nagashima 
(2009) 
17 1.1  
(0.6-
1.8) 
61.8  
(47-71) 
Cool-Tip 100% 
(Imagin
g) 
Follow-up  
19M (12-
28) ¹ 
- 9.6 (6.5-
17) 
Motoyoshi 
(2010) 
2x1
7 
1.5  
(0.5-
2.1) 
and 
1.2  
(0.5-
2.0) 
55 (33-
78) ¹ 
and 45  
(22-59) 
¹ 
StarBurst 100% 
(NADH, 
n=33), 
64.7% 
(H&E, 
n=34) 
Immediatel
y,  
delayed 30-
202 D 
Recurrence(
3) 
- 
Wiksell 
(2010) 
31 1.1±0.
3 (0.6-
1.5) 
63.6±8.
9 (46-
83) 
NeoDynamics 
AB 
84% 
(H&E) 
Immediatel
y 
Skin burn 
(1), muscle 
burn (2), 
pneumothor
ax (1) 
9.5±1.2  
(6.5-11) 
Hung 2x1 1.4±0. 60±12 LeVeen and 90% Immediatel Blistering 28±6 vs 
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Study N Size 
lesion 
(cm)* 
Age 
(years)
* 
Electrode
+
 CA  Resection* Complicatio
ns  
Treatme
nt time 
(min)* 
(2011) 0 3 vs 
1.3±0.
3 
vs 57±9 Cool-Tip and 
89% 
(H&E, 
NADH) 
y (5), 
coagulative 
changes to 
skin (n=4) 
12±0  
Kinoshita 
(2011) 
49 1.7  
(0.5-
3.0) 
61 (36-
82) ¹ 
Cool-Tip 61% 
(H&E 
and 
NADH) 
Immediatel
y 
Skin burn (2) 
, muscle 
burn (3) 
8.7 (3-
18) 
Ohtani 
(2011) 
41 1.3  
(0.6-
3.5) ¹ 
59 (38-
92) ¹ 
Cool-Tip 87.8% 
(H&E, 
NADH) 
Immediate  
(n=9), 
delayed 1-2 
M (n=32) 
Skin burn (1) 9 (6-15)¹ 
Tsuda 
(2011) 
28 2.2±1.
3 (0.6-
5.0) 
59.1  
(36-82) 
Cool-Tip 79% 
(NADH) 
Immediatel
y 
- - 
Yamamoto 
(2011) 
29 
(30) 
1.3  
(0.5-
1.9) 
55.9  
(38-78) 
Cool-Tip 92% 
(NADH, 
n=26) 
Follow-up  
17 (2-41) M 
Skin burn 
(3), 
overreaction 
(1) 
11.4 (6-
20) 
Noguchi 
(2012) 
19 1.3  
(0.5-
2.0) ¹ 
45 (22-
59) ¹ 
StarBurst 100% 
(NADH, 
n=18) 
30 (24-
202)D ¹ 
- 15  
Palussiere 
(2012) 
21 2.0¹ 79 (70-
88) ¹ 
LeVeen - Follow-up  
 49.6 (17-
77)M ¹ 
Skin burn 
(4), nipple 
retraction 
(3), 
recurrence 
(3) 
11 (4-19) 
Vilar (2012) 14 1.8  
(1.0-
2.5) 
56 (37-
71) 
LeVeen 50% 
(H&E) 
3 wk skin burn (1), 
fistula (1) 
- 
Manenti  
(2013) 
40 - 73±5  
(64-82) 
Miras PTV 92.5% 
(H&E, 
NADH) 
34 (30-45) 
D 
- 27 (24-
35) 
Yoshinaga 
(2013) 
6+8 1.2  
(0.6-
67 (45-
82) ¹ 
Cool-Tip 100% 
(n=7), 
100% 
(NADH, 
Immediate 
(n=6), 
follow-up  
39.9 M 
Skin burn (1) 9.6 (4.8-
14.7) ¹ 
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Study N Size 
lesion 
(cm)* 
Age 
(years)
* 
Electrode
+
 CA  Resection* Complicatio
ns  
Treatme
nt time 
(min)* 
2.0) ¹ n=5) (n=8) ¹ 
Schassburg
er (2014) 
18 1.0  
(0.6-
1.5) ¹ 
67 (46-
84) ¹ 
NeoDynamics 89% 
(CK8) 
14.5 (6-22) 
D¹ 
- 10 (8-14) 
¹ 
Waaijer 
(2014) 
15 1.1  
(0.4-
1.7) ¹ 
63 (50-
76) ¹ 
CelonProSurge 77% 
(n=13) 
Immediatel
y 
Pneumothor
ax (1), 
recurrence 
(1) 
13±0.2  
(6-26) 
CA = complete ablation, d= days, H&E = haematoxylin and eosin, m= months, min = minutes, N = number of 
patients, NADH = nicotinamide adenine dinucleotide, wk = weeks, yr = years. 
* Values are Mean±SD (range), unless indicated otherwise by ¹ in which case it is medium (range). 
+ 
Cool-Tip RF Needle Electrode (Radionics, Burlington, MA); Elektrotom 106 HiTT, (Berchtold, Germany); LeVeen 
needle electrode (RadioTherapeutics Corporation, Mountain View, CA); Miras PTV (University Hospital 
Policlinico Tor Vergata, Rome, Italy and INVATEC ITALIA, Roncadelle, Brescia, Italy); Unknown model type 
(NeoDynamics AB, Sweden); StarBurst radioprobe (RITA Medical Systems, Mountain View, California); bipolar 
radiofrequency ablation system was used (CelonProSurge150-T20, Olympus Winter & Ibe GmbH, Hamburg, 
Germany). 
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Table 1b: Study characteristics and outcomes for laser ablation 
Study N Size 
(cm)* 
Age 
(yr)* 
Device 
+ 
CA Complications Resection* Time 
(min)* 
Harries 
(1994) 
44 - - Diomed - Haemorrhage (1) 1-34 D 3.3-
12.5 
Mumtaz 
(1996) 
20 
(27) 
2.0 
(0.4-
3.3) ¹ 
57  
(34-
79) ¹ 
Diomed - - 5 (1-15) D ¹ 5.0-
8.3 
Akimov 
(1998) 
28+7 3.0  
(1.0-
6.0) ¹ 
53  
(38-
78) ¹ 
Nd:YAG - Gaseous rupture 
of the tumour (1), 
skin burn (4), 
recurrence (9) 
Delayed 
(n=28) 1-11 
D, follow-up 
(n=7) 20.5 
(5-64) M 
- 
Bloom 
(2001) 
40 0.95  
(0.5-
2.3) 
60  
(42-
80) 
Diomed - - 14.5 (0-70) 
D 
- 
Dowlatshahi 
(2002) 
54 1.3  
(0.5-
2.3) 
60  
(42-
80) 
Diomed 70%  Skin burn (2) 1-8 wk 25- 30 
Haraldsdottir 
(2008) 
24 1.4 
(0.5-
3.5) 
61  
(39-
84) 
Diomed 12.5% 
(H&E) 
Skin necrosis (2), 
recurrence (2) 
12 (4-23) D 30 
Van Esser 
(2009) 
14 1.7  
(0.8-
3.7) ¹ 
54.5  
(35-
85) ¹ 
Nd:YAG 50% 
(NADH) 
Skin burn (1),  
pneumothorax (1) 
Immediately 
 
21.4 
(15-
30) 
CA = complete ablation, d= days, H&E = haematoxylin and eosin, m= months, min = minutes, N = 
number of patients, NADH = nicotinamide adenine dinucleotide, wk = weeks, yr = years. 
* Values are Mean±SD (range), unless indicated otherwise by ¹ in which case it is medium (range). 
+ Diomed, (Cambridge, UK); Nd:YAG laser (Polar Ltd., Russia)  
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Table 1c: Study characteristics and outcomes of cryo-ablation 
Study N Size 
(cm)* 
Age 
(years)* 
Device 
type + 
CA Complication
s 
Resection* Time 
(min)* 
Pfleiderer 
(2002) 
15 
(16
) 
2.2±0.9
3  
(0.9-
4.0) 
60.3±9.
4 
 (38-80) 
CryoHit 31.3% Seroma (1) 1-5 D 52.4±7.
1 (41-
64) 
Tafra  
(2003) 
24 1.2±0.4  
(0.7-
2.0) 
61 (41-
78) 
Visica - - Immediatel
y 
15.8±7.
6  
(14¹) 
Sabel  
(2004) 
29 1.2±0.5  
(0.6-
2.0) 
52.5 
(34-77)¹ 
Visica 85% 
(H&E, 
n=27) 
- 14 (6-30) D 30 
Morin  
(2004) 
25 3.0 (1.2-
6.0) 
61.0 
(41-77) 
CryoHit 52% Minimal skin 
burn (?) and 
mastitis (?) 
4 wk 180 
Pfleiderer 
(2005) 
30 1.2 (0.5-
1.5)¹ 
61.5 
(48-80)¹ 
CryoHit 83% 
(H&E) 
Arterial 
bleeding (1), 
seroma (1) 
11±9.2 D 40-75 
Pusztaszer
i (2007) 
11 1.3 (0.5-
2.5) 
63 (52-
78) 
CryoHit 20% 
(H&E) 
Skin 
ulceration 
and/or 
necrosis (5) 
4-5 wk 20 
Littrup  
(2009) 
11 
(18 
_ 4 
LN) 
1.7±1.2  
(0.5-
5.8) 
62.5 Endocare 100% 
(CNB, 
n=6) 
 
- Follow-up  
22.8 M  
24.7 
(14-33) 
 
Manenti 
(2011) 
15 0.8±0.4  
(4-1.2) 
73±5 
(64-82) 
IceRod® 93.3% 
(H&E) 
Subcutaneou
s haematoma 
(2), 
ecchymosis 
(4) 
34 (30-45) 
D 
- 
Manenti 40 - 73±5  IceRod® 95% 
(H&E, 
- 34 (30-45) 
D 
- 
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Study N Size 
(cm)* 
Age 
(years)* 
Device 
type + 
CA Complication
s 
Resection* Time 
(min)* 
(2013) (64-82) NADH
) 
Luigi 
Cazatto 
(2015) 
23 1.4 (0.5-
2.8)¹ 
85 (56-
96)¹ 
IceSpher
e and 
IceRod® 
- Haematoma 
(3),  skin burn 
to 
imflammatio
n to skin 
retraction (1), 
haematoma 
to skin 
retraction (1), 
skin 
retraction to 
ulceration 
(1), 
recurrence 
(n=1) 
Follow-up  
14.6 M¹ 
29.4 
Simmons 
(2016) 
86 
(87
) 
1.2±0.3 
(0.5-
1.9) 
61.1±9.
3 (42-
81) 
Visica 75.9 
% 
(H&E) 
- <4 wk - 
CA = complete ablation, d= days, H&E = haematoxylin and eosin, m= months, min = minutes, N = 
number of patients, NADH = nicotinamide adenine dinucleotide, wk = weeks, yr = years. 
* Values are Mean±SD (range), unless indicated otherwise by ¹ in which case it is medium (range). 
+ CryoHit (Galil Medical, Yokneam, Israel); Endocare, (Irvine, California); IceRod® and IceSphere 
models (Galil Medical, Yokneam, Israel); Visica Cryoablation System (Sanarus Medical, Inc., 
Pleasanton, CA). 
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Table 1d: Study characteristics and outcomes for high intensity focused ultrasound (HIFU) 
Study n Size 
(cm)* 
Age 
(years)* 
Guidance 
and 
device + 
CA Resection* Complications Time 
(min)* 
Gianfelice  
(2003) 
12 2.8 
(0.1-
8.8) 
cm3 
60±9.6  
(45-74) 
MRI, 
ExAblate 
2000 
17% 
(H&E) 
Delayed  
(unknown 
time) 
Skin burn (2) 80 
(35-
133) 
  
Gianfelice  
(2003) 
17 2.5 
(0.1-
8.8) 
cm3 
61.2±8.9  
(48-76) 
MRI, 
ExAblate 
2000 
24% 
(H&E) 
3-21 D - - 
Gianfelice  
(2003) 
24 1.5 
(0.6-
2.5) 
74.2 (53-
92) 
MRI, 
ExAblate 
2000 
79% Follow-up  
20.2 M 
(12-39) 
Skin burn (1) - 
Wu  
(2003) 
23 3.1±0.8  
(2.0-
4.7) 
46.5±1.7 US, JC 
HAIFU 
100% 
(H&E) 
1-2 wk Skin burn (1) 78 
(45-
150) ¹ 
Wu  
(2005) 
22 3.4 
(2.0-
4.8) 
48.6(36-
68) 
US, JC 
HAIFU 
100% 
(H&E) 
Follow-up  
54.8 M 
(36-72) ¹ 
Recurrence 
(2) 
132 
(60-
180) ¹ 
Zippel  
(2005) 
10 2.2 56 (45-
72) 
MRI, 
ExAblate 
2000 
20% 7-10 D Skin burn (1) Max 
240 
Khiat  
(2006) 
25 
(26) 
3.3 
(0.1-
11.2) 
cm3 
61.3±11  
(45-87) 
MRI, 
ExAblate 
2000 
31% 
(8/26) 
3-21 D - - 
Furusawa  
(2006) 
28 1.3 
(0.5-
2.5) 
56.9 (41-
79) 
MRI, 
ExAblate 
2000 
53.5% 
(H&E) 
5-23 D Skin burn (1) 140 
(76-
231) 
Furusawa  
(2007) 
21 1.5 
(0.5-
5.0) ¹ 
54 (34-
72) ¹ 
MRI, 
ExAblate 
2000 
- 
 
Follow-up 
14 M (3-
26) 
Skin burn (2),  
recurrence (1) 
- 
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Study n Size 
(cm)* 
Age 
(years)* 
Guidance 
and 
device + 
CA Resection* Complications Time 
(min)* 
Cavallo- 
Marincola  
(2013) 
10 1.2 - MRI, 
Exablate 
2100 
60% 24-35 D - 140 
(80-
180) 
Merckel 
(2016) 
10 2.0±0.6 54.8±12.5 MRI, 
Sonalleve 
- 5.0±2.2 D White lumps 
(1) 
46±17 
(12-
75) 
Guan 
(2016) 
25 (2.1-
4.8) 
48 (22-
63) 
US, JC 
HAIFU 
- 1-2 wk Fever (3) 66 
(40-
132)¹ 
CA = complete ablation, d= days, H&E = haematoxylin and eosin, m= months, min = minutes, N = 
number of patients, NADH = nicotinamide adenine dinucleotide, wk = weeks, yr = years. 
* Values are mean ± SD (range), unless indicated otherwise by ¹ in which case it is medium (range). 
+ JC HAIFU (Chongqing Haifu Tech Co., Ltd., China); ExAblate 2000; InSightec-TxSonics, Haifa, Israel 
and Dallas, Tex); Sonalleve (Philips heathcare, Finland); 
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Table 1e: Study characteristics and outcomes for microwave ablation 
Study N Size 
(cm)* 
Age 
(years)* 
Device+ CA Complication
s 
Resection
* 
Time 
(min)* 
Gardne
r (2002) 
1
0 
4.3 (1-8) 58.5 (47-
82) 
Medifocu
s  
1000 APA 
- Flap necrosis 
(3), blister (1) 
5-27 D 34.7 (12-
40) 
Vargas 
(2004) 
2
5 
1.76 (0.7-
2.8) 
57.2 Medifocu
s  
1000 APA 
68% 
(H&E) 
Skin burn (3) 17 (6-38) 
D 
- 
Dooley 
(2010) 
4
1 
1.6 (0.7-
2.73) 
58.0 Medifocu
s  
1000 APA  
85.3% 
(H&E) 
Skin burn (3), 
nipple 
retraction (1),  
seroma (6), 
abscess (1) 
19.6 (7-
60) D 
- 
Dooley 
(2010) 
1
5 
3.65 (2.0-
7.8) 
45.1 (26-
72) 
Medifocu
s  
1000 APA  
- Skin burn (5 
treatments) 
Delayed 
(unknown) 
34.8 
Zhou 
(2012) 
4
1 
2.0±0.5 
(1.0-3.0) 
55.5±11.
4  
(38-78) 
- 90% 
(NADH
) 
Skin injury  
(1), pectoralis 
major injury 
(2) 
Immediate 4.48±2.0
3  
(3-10) 
Zhou 
(2014) 
1
2 
2.89±0.4
4 
 
54 (34-
61) ¹ 
- - - >3 wk 2.15 (1.3-
3) 
CA = complete ablation, d= days, H&E = haematoxylin and eosin, m= months, min = minutes, N = 
number of patients, NADH = nicotinamide adenine dinucleotide, wk = weeks, yr = years. 
* Values are Mean±SD (range), unless indicated otherwise by ¹ in which case it is medium (range). 
+ Medifocus-1000 APA (Celsion Corporation, Columbia, MD)  JU
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Table 2: Quality assessment (Yes/No) for (a) cohort studies and (b) randomized controlled trials. 
(a) Objective Incl. 
criteria 
Standardised Follow-
up 
With-
drawals 
Technique Histopathology Imaging 
Radiofrequency 
ablation 
27/0 26/1 25/2 27/0 11/3 (13 -) 12/15 0/27 
Cryo-ablation 10/0 8/2 9/1 9/1 4/1 (5 -) 3/7 2/8 
Laser ablation 7/0 4/3 7/0 6/1 3/2 (2 -) 3/4 1/6 
HIFU 10/0 9/1 8/2 5/5 10/0 3/7 3/7 
Microwave 
ablation 
4/0 3/1 4/0 4/0 1/0 (3 -) 0/4 0/4 
Combined 
technique 
1/0 1/0 1/0 1/0 1/0 0/1 0/1 
Study quality was assessed according to the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement. 
- no data available to answer  
 
(b) Adequate 
sequence 
generation 
Power 
analysis 
Concealed 
allocation 
Blinding Incomplete 
data 
addresses 
Free of 
other 
bias 
Free 
selective 
reporting 
HIFU U 0/2 U 0/2 0/2 2/0 2/0 
Microwave 
ablation 
U 0/2 U 0/2 1/1 2/0 2/0 
U = unspecified 
Study quality was assessed according to the “Risk Bias Tool” in the Cochrane Handbook. 
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